17th eso-esmo masterclass in clinical oncology€¦ · radiotherapy and tme compared with tme...
TRANSCRIPT
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
17th ESO-ESMO-EONS MasterclassManagement of rectal cancer
David Sebag-Montefiore Audrey and Stanley Burton Professor of Clinical Oncology Leeds Cancer Centre UK.@MontefioreD
+ Razvan Popescu17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Summary of topics
• Quality of imaging, surgery and pathology• Effectiveness of pre-operative radiotherapy• ESMO treatment guidelines• Evidence for (C)RT from clinical trials• Future directions
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Histopathology
+ve CRM = microscopic tumour <=1mm from the painted margin
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
MRI – mesorectal fascia
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Role of circumferential margin involvement in the local recurrence of rectal cancerAdam et al Lancet 1994;344;707-711
• All patients n=190 LR 29%
• “Curative resections” n=141 LR 23%
– CRM+ve (25%) n=35 LR 66%– CRM -ve (75%) n=106 LR 8%
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
CR07 – Plane of surgical specimenQuirke et al 2009
0
20
40
60
80
100
Local R
ecurrenc
e rate (%
)
0 1 2 3 4 5Time (Years)
Muscularis Propria 32 154
Intramesorectal 27 398
Mesorectal 19 604
Events Total
At risk: 154 135 111 72 47 25398 351 281 220 155 88604 552 435 297 192 112
0
20
40
60
80
100
Local R
ecurrenc
e rate (%
)
0 1 2 3 4 5Time (Years)0
20
40
60
80
100
Local R
ecurrenc
e rate (%
)
0 1 2 3 4 5Time (Years)
Muscularis Propria 32 154
Intramesorectal 27 398
Mesorectal 19 604
Events Total
At risk: 154 135 111 72 47 25398 351 281 220 155 88604 552 435 297 192 112At risk: 154 135 111 72 47 25398 351 281 220 155 88604 552 435 297 192 112
020406080
100
Disease
Free sur
vival rat
e (%)
0 1 2 3 4 5Time (Years)
Muscularis Propria 45 154Intramesorectal 100 398Mesorectal 139 604
Events Total
At risk: 154 128 102 66 44 25398 336 262 202 140 81604 514 391 279 179 108
020406080
100
Disease
Free sur
vival rat
e (%)
0 1 2 3 4 5Time (Years)
Muscularis Propria 45 154Intramesorectal 100 398Mesorectal 139 604
Events Total
At risk: 154 128 102 66 44 25398 336 262 202 140 81604 514 391 279 179 108
Local recurrence
Disease free survivalMesorectal Intra-
mesorectal
n=59653%
n=38234%
Muscularis propria
n=14113%
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Radiotherapy reduces LR for all planes of surgical excision Quirke et al Lancet 2009
Muscularispropria Intramesorectal% HR (95% CI) Mesorectal% HR (95% CI)All patients 13% 7% 0.48 (0.25-0.93) 4% 0.32 (0.16-0.64)
Selective post 16% 10% 0.49 (0.23-1.06) 7% 0.48 (0.23-1.00)Pre-op RT 10% 4% 0.52 (0.15-1.79) 1% 0.09 (0.02-0.49)
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma – Wong et al Cochrane review 2007
• 19 trials >8000patientsOverall mortality
Cause specific mortality
Local recurrence17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer-Caluwe Cochrane review 2012• 5 trials >2000 patients
Local Recurrence
Overall Survival
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer-Caluwe Cochrane review 2012
Acute Toxicity
Late Toxicity
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
• ESMO Guidelines statement“…….. rectal MRI for all tumours, including the earliest ones, is required in order to select patients for preoperative treatment and extent of surgery.”Mean extramural spread MRI 2.8mm Mean extramural spread path 2.81mm=
MERCURY Trial - Primary end point Radiology 2007 243: 132-139; BMJ 2006 333:779-783
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
MERCURY results
• MRI assessment of the CRM predicts DFS and LR– Taylor FG et al, J Clin Oncol.2014 Jan 1;32(1):34-43• Comparison of MR and Histopath response to CRT– Patel UB et al Ann Surg 2012• MRI detected tumour response for locally advanced rectal cancer predicts survival outcomes– Patel U, Journal Of Clinical Oncology 2011; 29:3753-60 • Preop High-resolution MRI Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone– Taylor FG et al Annals of Surgery 2011 253:711-719 17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
MRI – Selection for pre-op (C)RT
Margin at risk = Pre-op CRT
Options
•Surgery alone•Surgery then post-op CRT•Pre-op SCPRT then surgery
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Local recurrence by T3 substageSebag-Montefiore et al ESTRO 2012
N=184 N=309 N=150
3% vs 6%3% vs 10%
10%vs 22%
T3a <=1mmT3b >1-5mmT3c>5-15mm
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
NICE guidelines 2011 -Risk of locoregional failure
MRI findingsHigh risk A threatened (<1 mm) or breached
resection margin or low tumours encroaching onto the inter-sphincteric plane or with levator involvement
Moderate risk
Any cT3b or greater, in which the potential surgical margin is not threatened or any suspicious lymph node not threatening the surgical resection margin or the presence of extramural vascular invasion
Low risk T1 or cT2 or cT3a and no lymph node involvement
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Rectal Cancer: ESMO Clinical Practice Guidelines Annals of Oncology 2017
Intermediate/ bad Advanced(ugly)Early(good)cT1-2; cT3aT3 (b) if mid or high N0 (or cN1 if high)MRF –ve; EMVI –ve
cT2 very low,cT3 mrf –ve (unless cT3a(b) and mid or high rectum, N1-2, EMVI +ve, limited cT4aN0
cT3 MRF +vecT4a,bLateral node +ve
Surgery (TME alone)
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Complete data (Surgery MRI and Pathology) n=477Consented to follow up n=386Complete data with FU n=374
MRI defined good prognosis n=141 MRI defined bad prognosis n=234Surgery alone n=122 Pre operative radiotherapy n=19LR 4/122 (3%)5yr DFS 85%
MR stage T2N0 57T3aN0 24T3bN0 19T2N+ 7T3a N+ 6T3bN+ 9
“Good prognosis” rectal cancer best managed by surgery alone Taylor et al Annals of Surgery 2011
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Side effects of Preop RT
Rectal and sexual function is worse after preoperative radiotherapy and TME compared with TME alone: Results from many randomised studies
•u Peeters K, J Clin Oncol 2015;25:6199 •u Dahlberg M, Dis Colon Rectum 1998;41:543 •u Stephens RJ, J Clin Oncol 2010;28:4233 •u Marijnen CAM, J Clin Oncol 2005;23:1847 •u Lundby L, Lancet 1997;350:564 •u Lange MM, Br J Surg 2007;94:1278 17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Dutch TME and MRC CR07 trial design
n = 1350
Clinically operable adenocarcinoma of the rectum <15cm from anal verge; no metastases
Adjuvant chemotherapy given as per local policy – CR07
PRE SEL POST
Pre-operative RT25Gy / 5F
Surgery
Pathology
Surgery
Pathology
CRM-ve CRM+ve
Post-op (C)RTDutch RTCR07 CRT
No CRT
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
CR07 and Dutch TME trial data
PRE SEL POST NNTDutch TME trial Lancet Oncology 2011
Stage I <1% 3% 10 yreligible 50MRC CR07 ESTRO 2012
Stage I 3% 5% 5 yr ITT 50T2 or less 5% 7% 5yr ITT 50T3a 3% 6% 5 yr ITT 3317th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Dutch TME and MRC CR07 trialsVan Gijn et al Lancet Oncology 2011Sebag-Montefiore et al Lancet 2009
Dutch TME trial
MRC CR07
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
CRT – 5FU 225mg/m2 cont50.4Gy CRT
Short coursePre op (25Gy in 5F)
N=326S
5FU/LV x4S
5FU/LV x 6
TROG AGIT LSSANZ RACS trial Ngan et al JCO 2012
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
TROG AGIT LSSANZ RACS trial Ngan et al JCO 2012
CRT
SCPRT
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Pre vs. Postop CRTCAO/ARO/AIO-94
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Rectal Cancer: ESMO Clinical Practice Guidelines Annals of Oncology 2017
Intermediate/ bad Advanced(ugly)Early(good)cT1-2; cT3aT3 (b) if mid or high N0 (or cN1 if high)MRF –ve; EMVI –ve
cT2 very low,cT3 mrf –ve (unless cT3a(b) and mid or high rectum, N1-2, EMVI +ve, limited cT4aN0
cT3 MRF +vecT4a,bLateral node +ve
Surgery (TME alone)25Gy in 5ForCRTFollowed by TME
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Rectal Cancer: ESMO Clinical Practice Guidelines Annals of Oncology 2017
Intermediate/ bad Advanced(ugly)Early(good)cT1-2; cT3aT3 (b) if mid or high N0 (or cN1 if high)MRF –ve; EMVI –ve
cT2 very low,cT3 mrf –ve (unless cT3a(b) and mid or high rectum, N1-2, EMVI +ve, limited cT4aN0
cT3 MRF +vecT4a,bLateral node +ve
Surgery (TME alone)25Gy in 5ForCRTFollowed by TME
CRT? Neoadjuvant ChemoFollowed by TME
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
ESMO 2017 Guidelines Risk Groups
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Pre-operative Chemoradiotherapyregimen
• Fluorpyrimidine– 5FU bolus or as continuous infusion– Oral Capecitabine• Radiotherapy dose– ESMO guidelines• 45-50.4Gy intermediate risk• 50.4Gy advanced• Radiotherapy target volume– External iliac nodes not routinely included– In intermediate risk superior limit can be lowered to S2/3– Low level evidence for the role of boost in advanced17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Intensification of CRT
• Addition of drug or targeted therapy to CRT– Disappointing (0xaliplatin ph III, VEGF/EGFR ph II)– Clinical trials• Neoadjuvant chemotherapy + pre-op CRT– More evidence (encouraging ph II eg EXPERT)• Short course radiotherapy + neoadjuvant chemotherapy– RAPIDO trial ongoing• Neoadjuvant chemotherapy – PROSPECT trial ongoing• Radiotherapy dose escalation– Clinical trials17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Summary of doublet and triplet CRT
• Oxaliplatin– Phase III disappointing• Irinotecan– ARISTOTLE trial recruiting• EGFR– Single arm phase II – inferior early pathological end points• Vascular targeted– Limited data
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
RAPIDO Ph III Trial n=940Hospers et al ECCO 2017
1 week 18 weeks 2-4 weeksS
5x5 CAPE + OXALIPLATIN
1 week
5.5 weeks 6-8 weeks 6-8 weeks 24 weeksRT+CAPE CAPE + OXALIPLATIN
35
MRI definedcT4a,cT4b,cN2, EMVI+, Lat LN+
S
14 weeks
24 weeksOverall ypT0 = 23%
Variable use by countryDiffering Standards of Care
Use of 5x5
MRI defined Locally advanced
18 weeks NAC
Standard of care control arm
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Intensification of treatment using neoadjuvant chemo separate from RT
SELECTION FOR NEOADJUVANT CHEMOTHERAPY •u Extensive EMVI •u Disease breaching/outside the mesorectal fascia
• NEO-ADJUVANT BEFORE CRT• IN THE INTERVAL BETWEEN CRT AND TME OP
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Intensification of treatment using neoadjuvant chemo separate from RT
NEO-ADJUVANT CHEMO BEFORE CRTEXPERT, EXPERT-C Trials
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Intensification of treatment using neoadjuvant chemo separate from RT
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
SUMMARY
• Preoperative CRT better than postop • SCPRT=CRT for resectable cancers • SCPRT/CRT improves local recurrence but not DFS or OS • If CRM threatened on MRI needs response so CRT • Low rectal cancers (below the levators) often have threat to CRM and may have LPLN 17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
ESMO Rectal Cancer GuidelinesAnnals of Oncology 28 (Supplement 4): iv22–iv40, 2017
SoCTME aloneAVOID RTTME alone if high quality or plusSCPRT/CRT
SCPRTorCRTThen TMECRT orSCPRT + FOLFOXthen TME
KeyMessages
cT1-2; cT3a/b if middle or high cN0 (cN1 ighigh) MRF clear; no EMVIcT3a/b very low levatorsclear. MRF clear, cT3a/b in mid or high rectum, cN1-2 (not extranodal), no EMVI
cT3c/d or very low, levators not threatened, MRF clear. cT3c/d mid rectum, cN1-N2 (extranodal), EMVI +vecT3 with MRF involvedcT4b, levators threatened, lateral node +ve
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Organ Preservation
Low risk Moderate risk Highrisk
SCPRT CRTConsider Consider
CCR W+W
Organ preservation trialsAllows intensification
• Highly selected• CRT not changed• Surgery plan changed• Intensive FU for LR
(C)RTCCR W+WTEMContact
• RT not given• Intensification poss• “Double jeopardy”• Highest CCR• Intensive FU for LR17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Habr Gama data IJROBP 2014 88:822-8
CRT n=183CCR n=90
Early regrowthn=178 weeks
12 months Sustained CRn=73
Sustained CRn=62
Late regrowthn=11
AR n=7APER n=4FTLEn=5 Unresn=1
AR n=0APER n=7FTLE n=2Brachy n=1 Unresn=1
Unres n=2
Unres n=2Organ preservation n= 70 Unresectable pelvic disease n=6
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Organ Preservation – Key publications
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
TREC - Study Design
50
Rectal CancerT1-2 N0
RandomiseRadical Surgery Organ Preservation
Clinical Equipoise?YesNo No
25Gy in 5F8-10 weeks
TEMS• Feasibility – yes 63 randomised• Early information on OP17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
Deferral of rectal surgery studyRoyal Marsden Study – [email protected] cancer receiving CRT and ,agrees to surgery in needed
MRI 4 weeks post CRT + MDT discussionNo visible tumour Visible tumour good PR Stable disease
CONSIDERATION OF TRIALMRI and FDG PET at 8 weeks
No visible tumour or further regression No further regression / growth of disease
Surgical resectionProtocol defined follow up17th
ESO-E
SMO M
asterc
lass in
Clin
ical O
ncology
Leeds Institute of Cancer and Pathology
Radiation Therapeutics
STARTREC – Study designPhase II/III clinical trial
TME
W&W TEM
Poor/inadequate responseLittle or no residual disease Good response:residual disease
high risk conversion TME
evaluation
cT1-3b N0
TMEOrgan preservationRadical Surgery
5x5 GyOrgan preservation
CRT
week 11-13 – central review
week 1-5
CCR Not CCRweek 16-20 – central review
17th E
SO-ESM
O Maste
rclass
in C
linica
l Onco
logy